NeoGenomics, Inc.
12701 Commonwealth Drive
Suite 9
Fort Myers
Florida
33913
United States
Tel: 239-768-0600
Fax: 239-768-0711
Website: http://www.neogenomics.org/
Email: info@neogenomics.org
266 articles about NeoGenomics, Inc.
-
Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma
2/11/2022
Inivata, a leader in liquid biopsy, announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma.
-
NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
2/2/2022
NeoGenomics, Inc. announced today that it plans to release its fourth quarter 2021, financial results on Wednesday, February 23, 2022.
-
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
1/24/2022
NeoGenomics, Inc. announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that include patients with similar findings.
-
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
1/11/2022
NeoGenomics, Inc. today announced that its liquid biopsy focused subsidiary Inivata Limited has received the CE mark for its RaDa assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC).
-
NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary
12/13/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of David Eberhard MD, PhD as Chief Medical Officer of its liquid biopsy focused subsidiary Inivata Limited.
-
NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancer
12/10/2021
NeoGenomics, Inc. announced it will use Thermo Fisher Scientific's Ion Torrent Genexus System to deliver results in as little as a single day,
-
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
11/30/2021
NeoGenomics, Inc. today announced that Mark Mallon, Chief Executive Officer, Bill Bonello, President - Informatics Division, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Stephens Annual Investment Conference 2021 held in Nashville, Tennessee on Friday, December 3, 2021 at 9:00am.
-
NeoGenomics Appoints Dave Daly to Its Board of Directors
11/10/2021
NeoGenomics, Inc. has appointed Dave Daly to serve on its Board of Directors. Dave Daly joined our Board of Directors effective November 10, 2021.
-
NeoGenomics Reports Revenue of $121 Million in the Third Quarter
11/4/2021
NeoGenomics, Inc. today announced its third-quarter results for the period ended September 30, 2021.
-
NeoGenomics Announces Leadership Team Transition
11/4/2021
NeoGenomics, Inc. announced today an upcoming leadership team transition. William Bonello will be named Chief Financial Officer as of January 1, 2022.
-
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
10/19/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that its liquid biopsy focused subsidiary Inivata Limited has entered into a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata's liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.
-
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays
10/19/2021
Inivata, a leader in liquid biopsy, announced a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata’s liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.
-
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
10/13/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing and global contract research services, announced that it plans to release its third quarter 2021, financial results on Thursday, November 4, 2021.
-
NeoGenomics Announces Board of Directors' Transition
10/12/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced a transition in the leadership of its Board of Directors.
-
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
9/9/2021
NeoGenomics, Inc. today announced that its liquid biopsy focused subsidiary Inivata Limited alongside collaborators, will present new data on its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst-Lung liquid biopsy test at the European Society on September 16-21, 2021.
-
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
9/1/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that Mark Mallon, Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Morgan Stanley 19th Annual Global Healthcare Conference, on Tuesday, September 14, 2021 at 10:15am ET.
-
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
8/6/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetics testing services, announced its second-quarter results for the period ended June 30, 2021.
-
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
7/14/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing and global contract research services, announced that it plans to release its second quarter 2021, financial results on Friday, August 6, 2021.
-
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
6/18/2021
NeoGenomics, Inc.announced today that it has completed its acquisition of Inivata Ltd.
-
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
5/27/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that senior management will be participating virtually in multiple upcoming institutional investor conferences.